Recordati Industria Chimica e Farmaceutica S.p.A (0KBS) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Recordati Industria Chimica e Farmaceutica S.p.A €34.35, price €52.65, upside -34.8%, quality 69 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range €31.99 – €58.00 · fair‑value band €22.43 – €44.30 · the €52.65 price screens above the €34.35 fair value. Dashed = 300-day average. As of Sep 23, 2026.
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments.
Show more
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops Maapliv for maple syrup urine disease; Isturia for endogenous Cushing's syndrome; Cystadrops treatment of the ocular manifestations of cystinosis; Carbaglu for hyperammonemia due to n-acetyl glutamate synthase deficiency; Qarziba for neuroblastoma patients and patients with relapsed or refractory neuroblastoma; and Fotivda for renal cell carcinoma. It also develops Sylvant for idiopathic multicentric castleman diseases; Caphosol for oral mucositis; ENJAYMO for hemolysis in adults with cold agglutinin disease; Zanidip, Zanipress, Vazkepa, and Logimax for hypertension; Urorec and Avodart for symptoms of benign prostatic hyperplasia; and Livazo for dyslipidemia; Combodart/Duodart; Seloken for angina pectoris, myocardial infarction and cardiac rhythm disorders, as well as hypertension and functional heart disorders. In addition, the company offers Procto-Glyveno for internal and external hemorrhoids; Polydexa, Isofra, and Otofa for ear, nose and throat infections; Isturisa, for Cushing's syndrome; Normosang, human hemin; Juxtapid, homozygous familial hypercholesterolemia;Ledaga, mycosis fungoides, T-cell cutaneous lymphoma;Tergynan, an anti-infective for gynecological infections; CitraFleet and Phosphosoda as bowel cleansers; Lomexin for gynecological and dermatological infections; Hexaspray, treatments for the oral cavity; Magnesio Supremo, a dietary supplement; Reaglia for schizophrenia; Eligard for hormone-dependent prostate cancer; and pasireotide in Phase II trial for patients with post-bariatric hypoglycemia, as well as other products. The company was founded in 1926 and is headquartered in Milan, Italy.
Stock analysis
Recordati Industria Chimica e Farmaceutica S.p.A (0KBS) currently trades at €52.65, while our model-based Fair Value estimate is €34.35, 34.8% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of €35.45 per share, and 0 of the 24 models we run sit above the €52.65 price.
Bear case: the Asset-Based group reads lowest at €4.59, and 24 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: €22.43 (bear) to €44.30 (bull), the price of €52.65 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 69/100 (solid quality), in the Industrials sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Recordati Industria Chimica e Farmaceutica S.p.A reported revenue of €1.4B in FY2020 versus €1.2B in FY2016, a compound +5.9%/yr. Reported net income was €355M in FY2020, compounding +10.6%/yr from FY2016.
Key figures
Market cap €9.8B · P/S ratio 3.70 · Dividend yield 2.5% · Net margin 24.5% · Return on equity 23.4% · Return on assets (EBIT) 19.0% · Operating margin 32.4% · Revenue (TTM) €2.7B.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 2% below its 52-week high and 21% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Industrials peers we cover trades at −40% fair-value upside, at −35%, 0KBS screens cheaper than that median.
Fair Value models
Bear €22.43Fair Value €34.35Bull €44.30
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−2.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.0%
’16
’17
’18
’19
’20
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
28.4% (2016) → 32.4% (2020)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no share-count history
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Recordati Industria Chimica e Farmaceutica S.p.A Fair Value". https://www.fairvalue-calculator.com/stock/0KBS
Frequently asked questions
Is Recordati Industria Chimica e Farmaceutica S.p.A (0KBS) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of €34.35 versus a price of €52.65, about −35% upside (overvalued).
What is the fair value of 0KBS?
Our model-based fair value for Recordati Industria Chimica e Farmaceutica S.p.A is €34.35 (as of Sep 23, 2026), built from audited fundamentals. The current price: €52.65.
What is the quality score of 0KBS?
Recordati Industria Chimica e Farmaceutica S.p.A has a Quality Score of 69/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Recordati Industria Chimica e Farmaceutica S.p.A (0KBS)?
Our model-based price target is the fair value of €34.35 (as of Sep 23, 2026) from 24 valuation models. Cautious scenario €22.43, optimistic scenario €44.30. It is a calculation from audited fundamentals, not an analyst target.
What is the Recordati Industria Chimica e Farmaceutica S.p.A stock forecast for 2026?
Our models put fair value at €34.35, about −35% upside versus a price of €52.65 (overvalued). Cautious scenario €22.43, optimistic scenario €44.30. The calculation is refreshed regularly with new filings.
What is the revenue of Recordati Industria Chimica e Farmaceutica S.p.A (0KBS)?
Recordati Industria Chimica e Farmaceutica S.p.A reported trailing-twelve-month revenue of about €2.7B (latest available figure, as of Sep 23, 2026).
Does Recordati Industria Chimica e Farmaceutica S.p.A pay a dividend?
Recordati Industria Chimica e Farmaceutica S.p.A currently shows a dividend yield of about 2.55% relative to its recent price (as of Sep 23, 2026).
What is the intrinsic value of Recordati Industria Chimica e Farmaceutica S.p.A (0KBS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Recordati Industria Chimica e Farmaceutica S.p.A it is €34.35 per share (as of Sep 23, 2026), against a price of €52.65. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Recordati Industria Chimica e Farmaceutica S.p.A stock overvalued or undervalued in 2026?
As of Sep 23, 2026, 0KBS trades above its calculated fair value: price €52.65, fair value €34.35, a gap of about −35% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0KBS?
No. The price is what the market pays today (€52.65); the fair value is what the company's own numbers justify (€34.35). For Recordati Industria Chimica e Farmaceutica S.p.A the two are €18.30 per share apart. That gap is exactly why we show both numbers side by side.
How much is Recordati Industria Chimica e Farmaceutica S.p.A worth?
The market values Recordati Industria Chimica e Farmaceutica S.p.A at about €9.8B (market capitalisation, as of Sep 23, 2026). Per share that is €52.65; our models calculate a fair value of €34.35 per share.
What do the bullish and bearish scenarios say about 0KBS?
Our models span a range for Recordati Industria Chimica e Farmaceutica S.p.A: cautious scenario €22.43, base €34.35, optimistic €44.30 per share (as of Sep 23, 2026, price €52.65). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 0KBS from its 52-week high?
Recordati Industria Chimica e Farmaceutica S.p.A trades at €52.65, about 2% below its 52-week high of €53.48 and 21% above the low of €43.50 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of €34.35 is for.
Which stocks are comparable to Recordati Industria Chimica e Farmaceutica S.p.A?
From the same area (Industrials) we also value Contemporary Amperex Technology Co, Delta Electronics (Thailand) Public Company, Larsen & Toubro Limited, Samsung C&T Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Recordati Industria Chimica e Farmaceutica S.p.A stock attractive at the current price?
The data as of Sep 23, 2026: price €52.65, calculated fair value €34.35 (−35%), Quality Score 69/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0KBS calculated?
We run Recordati Industria Chimica e Farmaceutica S.p.A through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €34.35, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Recordati Industria Chimica e Farmaceutica S.p.A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Recordati Industria Chimica e Farmaceutica S.p.A (0KBS)?
The closing price on Oct 2, 2026 was €52.65. Our model-based fair value is €34.35, about −35% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Recordati Industria Chimica e Farmaceutica S.p.A right now?
The price sits above even our optimistic bull case (€44.30). The favourable scenario is already priced in. Solid but not exceptional quality (69/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (€22.43 to €44.30) leaves room in how you read the outcome.
Key figures of Recordati Industria Chimica e Farmaceutica S.p.A
How large is the market capitalisation of Recordati Industria Chimica e Farmaceutica S.p.A (0KBS)?
The market capitalisation of Recordati Industria Chimica e Farmaceutica S.p.A is €9.8B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Recordati Industria Chimica e Farmaceutica S.p.A (0KBS)?
The price-to-sales ratio of Recordati Industria Chimica e Farmaceutica S.p.A is 3.70 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Recordati Industria Chimica e Farmaceutica S.p.A (0KBS)?
The dividend yield of Recordati Industria Chimica e Farmaceutica S.p.A is 2.5%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Recordati Industria Chimica e Farmaceutica S.p.A (0KBS)?
The net margin of Recordati Industria Chimica e Farmaceutica S.p.A is 24.5% (fiscal year 2020). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Recordati Industria Chimica e Farmaceutica S.p.A (0KBS)?
The return on equity (ROE) of Recordati Industria Chimica e Farmaceutica S.p.A is 23.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Recordati Industria Chimica e Farmaceutica S.p.A (0KBS)?
On an EBIT basis the return on assets of Recordati Industria Chimica e Farmaceutica S.p.A is 19.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Recordati Industria Chimica e Farmaceutica S.p.A (0KBS)?
The operating margin of Recordati Industria Chimica e Farmaceutica S.p.A is 32.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Recordati Industria Chimica e Farmaceutica S.p.A (0KBS)?
Revenue at Recordati Industria Chimica e Farmaceutica S.p.A is growing +4.9% versus a year earlier (3y avg +4.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Recordati Industria Chimica e Farmaceutica S.p.A (0KBS)?
Earnings per share at Recordati Industria Chimica e Farmaceutica S.p.A are growing +22.4% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
